Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms
Year: 2024
Type: review
Abstract: Glioblastoma is the most common and lethal central nervous system malignancy with a median survival after progression of only 6-9 months. Major biochemical mechanisms implicated in glioblastoma recurrence include aberrant molecular pathways, a recurrence-inducing tumor microenvironment, and epigenetic modifications. Contemporary standard-of-care (surgery, radiation, chemotherapy, and tumor treating fields) helps to control the primary tumor but rarely prevents relapse. Cytoreductive treatment such as surgery has shown benefits in recurrent glioblastoma; however, its use remains controversial. Several innovative treatments are emerging for recurrent glioblastoma, including checkpoint inhibitors, chimeric antigen receptor T cell therapy, oncolytic virotherapy, nanoparticle delivery, laser interstitial thermal therapy, and photodynamic therapy. This review seeks to provide readers with an overview of (1) recent discoveries in the molecular basis of recurrence; (2) the role of surgery in treating recurrence; and (3) novel treatment paradigms emerging for recurrent glioblastoma.
DOI: 10.3390/ijms25126733
Authors: Christopher Chang, Velina S. Chavarro, Jakob V. E. Gerstl, Sarah E. Blitz, Lennard Spanehl, Daniel Dubinski, Pablo A. Valdes, Lily N. Tran, Saksham Gupta, Luisa Esposito, Debora Mazzetti, Florian A. Gessler, Omar Arnaout, Timothy R. Smith, Gregory K. Friedman, Pierpaolo Peruzzi, Joshua D. Bernstock
Institutions: Brown University, Brigham and Women's Hospital, Harvard University, University of Rostock, The University of Texas Medical Branch at Galveston, Saint Camillus International University of Health and Medical Sciences, The University of Texas MD Anderson Cancer Center, Koch Institute for Integrative Cancer Research At MIT, Massachusetts Institute of Technology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,296
OpenAlex ID: W4399863580